{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-020353","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.585118+00:00","generated_at":"2026-05-20T13:11:07.389493+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gyre Therapeutics raises $20M in public offering for Phase 2 F351 trial","bullets":["Issued 2,222,222 shares at $9.00/share; underwriters have 30-day option for 333,333 additional shares.","Net proceeds estimated at $18.5M after discounts and expenses.","Funds U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, R&D, and working capital.","Offering expected to close May 27, 2025; Jefferies LLC is sole book-running manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-020353","json":"https://secwatch.observer/filing/0001140361-25-020353.json","markdown":"https://secwatch.observer/filing/0001140361-25-020353.md","text":"https://secwatch.observer/filing/0001140361-25-020353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/0001140361-25-020353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/ef20049643_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T13:11:07.389493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}